Skip to content

Nasdaq · CIK 0001750284

OLMA Olema Pharmaceuticals, Inc.

Insider trading from SEC Form 4. Last filing 39 d ago. Close $7.82 on Oct 9, 2026, +1% from the 52-week low and -78% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company

Price and insider trades, last year

OLMAOct 9, 2026 · close 7.82

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Olema Pharmaceuticals, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
32WeakBain Capital Life Sciences Investors, LLC
owner
buy
$1.7M
300,000 shares
+4%-
48ModerateG. Walmsley Graham
director
buy
$4.7M
700,761 shares
--
75NotableG. Walmsley Graham
director
sell
$4.7M
700,761 shares
-100%-
55ModerateG. Walmsley Graham
director
buy
$4.7M
700,761 shares
+99%-
75NotableG. Walmsley Graham
director
sell
$4.7M
700,761 shares
-100%-
75NotableSean Bohen
PRESIDENT AND CEO
sell
$986k
109,502 shares
-31%-
41ModerateCyrus Harmon
director
sell
$148k
16,393 shares
-2%-
44ModerateShane William Charles Kovacs
CH. OPERATING & FINANCIAL OFF.
sell
$317k
35,159 shares
-6%-
43ModerateDavid C. Myles
CH. DISCOV. & NON-CLIN DEV OFF
sell
$235k
26,066 shares
-4%-
48ModerateNaseem Zojwalla
CHIEF MEDICAL OFFICER
sell
$250k
27,805 shares
-19%-
60NotableG. Walmsley Graham
director
sell
$17M
1,175,000 shares
-84%-

Transactions

The last 51 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 1, 2026Jason O'Byrne
CHIEF FINANCIAL OFFICER
AGrant or award
Stock Option (Right to Buy)derivative
+650,000$0.00$0650,00039 d ago
Feb 28, 2025Sean Bohen
PRESIDENT AND CEO
AGrant or award
Stock Option (Right to Buy)derivative
+650,000$0.00$0650,000Mar 3, 2025
Feb 28, 2025Shane William Charles Kovacs
CH. OPERATING & FINANCIAL OFF.
AGrant or award
Stock Option (Right to Buy)derivative
+320,000$0.00$0320,000Mar 3, 2025
Jan 10, 2025Bvf Partners L P/il
director, other
DDisposition to issuer
Common stock, $0.0001 par value
-235,450--2,655,977Jan 14, 2025
Jan 10, 2025Bvf Partners L P/il
director, other
DDisposition to issuer
Common stock, $0.0001 par value
-161,810--2,003,966Jan 14, 2025
Jan 10, 2025Bvf Partners L P/il
director, other
DDisposition to issuer
Common stock, $0.0001 par value
-22,740--347,970Jan 14, 2025
Jan 10, 2025Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+235,450--3,291,004Jan 14, 2025
Jan 10, 2025Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+161,810--2,627,590Jan 14, 2025
Jan 10, 2025Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+22,740--336,288Jan 14, 2025
Jan 8, 2025Bain Capital Life Sciences Investors, LLC
owner
POpen-market purchase
Common Stockindirect: See footnotes
+300,000$5.76$1.7M7,800,000Jan 13, 2025
Jan 10, 2025Bain Capital Life Sciences Investors, LLC
owner
JOther
Common Stockindirect: See footnotes
-3,500,000--4,300,000Jan 13, 2025
Jan 10, 2025Bain Capital Life Sciences Investors, LLC
owner
JOther
Pre-Funded Warrant (right to buy)derivativeindirect: See footnotes
+3,500,000--3,500,000Jan 13, 2025
Dec 13, 2024G. Walmsley Graham
director
SOpen-market sale
Common Stockindirect: See note
-700,761$6.75$4.7M0Dec 18, 2024
Dec 13, 2024G. Walmsley Graham
director
POpen-market purchase
Common Stockindirect: See note
+700,761$6.75$4.7M700,761Dec 18, 2024
Dec 16, 2024Naseem Zojwalla
CHIEF MEDICAL OFFICER
MOption exercise
Common Stock
+14,000$4.87$68k129,509Dec 17, 2024
Dec 17, 2024G. Walmsley Graham
director
SOpen-market sale
Common Stockindirect: See note
-700,761$6.75$4.7M0Dec 17, 2024
Dec 16, 2024Naseem Zojwalla
CHIEF MEDICAL OFFICER
MOption exercise
Stock Option (Right to Buy)derivative
-14,000$0.00$0112,840Dec 17, 2024
Dec 17, 2024G. Walmsley Graham
director
POpen-market purchase
Common Stockindirect: See note
-700,761$6.75$4.7M1,408,875Dec 17, 2024
Dec 9, 2024Sean Bohen
PRESIDENT AND CEO
AGrant or award
Common Stock
+204,750$0.00$0351,164Dec 11, 2024
Dec 9, 2024Cyrus Harmon
director
AGrant or award
Common Stock
+29,250$0.00$0780,533Dec 11, 2024
Dec 9, 2024Shane William Charles Kovacs
CH. OPERATING & FINANCIAL OFF.
AGrant or award
Common Stock
+68,250$0.00$0578,708Dec 11, 2024
Dec 9, 2024David C. Myles
CH. DISCOV. & NON-CLIN DEV OFF
AGrant or award
Common Stock
+48,750$0.00$0624,399Dec 11, 2024
Dec 9, 2024Naseem Zojwalla
CHIEF MEDICAL OFFICER
AGrant or award
Common Stock
+52,000$0.00$0143,314Dec 11, 2024
Dec 10, 2024Sean Bohen
PRESIDENT AND CEO
SOpen-market sale
Common Stock
-52,328$9.37$490k298,836Dec 11, 2024
Dec 10, 2024Cyrus Harmon
director
SOpen-market sale
Common Stock
-8,256$9.37$77k772,277Dec 11, 2024
Dec 10, 2024Shane William Charles Kovacs
CH. OPERATING & FINANCIAL OFF.
SOpen-market sale
Common Stock
-16,803$9.37$157k561,905Dec 11, 2024
Dec 10, 2024David C. Myles
CH. DISCOV. & NON-CLIN DEV OFF
SOpen-market sale
Common Stock
-12,452$9.38$117k611,947Dec 11, 2024
Dec 10, 2024Naseem Zojwalla
CHIEF MEDICAL OFFICER
SOpen-market sale
Common Stock
-13,283$9.37$124k130,031Dec 11, 2024
Dec 11, 2024Shane William Charles Kovacs
CH. OPERATING & FINANCIAL OFF.
SOpen-market sale
Common Stock
-17,950$8.66$155k543,955Dec 11, 2024
Dec 11, 2024Cyrus Harmon
director
SOpen-market sale
Common Stock
-7,958$8.66$69k764,319Dec 11, 2024
Dec 11, 2024David C. Myles
CH. DISCOV. & NON-CLIN DEV OFF
SOpen-market sale
Common Stock
-13,314$8.66$115k598,633Dec 11, 2024
Dec 11, 2024Naseem Zojwalla
CHIEF MEDICAL OFFICER
SOpen-market sale
Common Stock
-14,202$8.66$123k115,829Dec 11, 2024
Dec 11, 2024Sean Bohen
PRESIDENT AND CEO
SOpen-market sale
Common Stock
-55,907$8.66$484k242,929Dec 11, 2024
Dec 11, 2024David C. Myles
CH. DISCOV. & NON-CLIN DEV OFF
SOpen-market sale
Common Stock
-300$9.39$2,817598,333Dec 11, 2024
Dec 11, 2024Shane William Charles Kovacs
CH. OPERATING & FINANCIAL OFF.
SOpen-market sale
Common Stock
-406$9.39$3,812543,549Dec 11, 2024
Dec 11, 2024Cyrus Harmon
director
SOpen-market sale
Common Stock
-179$9.39$1,681764,140Dec 11, 2024
Dec 11, 2024Sean Bohen
PRESIDENT AND CEO
SOpen-market sale
Common Stock
-1,267$9.39$12k241,662Dec 11, 2024
Dec 11, 2024Naseem Zojwalla
CHIEF MEDICAL OFFICER
SOpen-market sale
Common Stock
-320$9.39$3,005115,509Dec 11, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
DDisposition to issuer
Common stock, $0.0001 par value
-1,797,527--2,891,427Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
DDisposition to issuer
Common stock, $0.0001 par value
-1,418,736--2,165,776Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
DDisposition to issuer
Common stock, $0.0001 par value
-153,441--370,710Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+1,797,527--1,797,527Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+1,418,736--1,418,736Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+153,441--153,441Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+1,258,027$9.08$11M3,055,554Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+1,047,044$9.08$9.5M2,465,780Dec 4, 2024
Dec 4, 2024Bvf Partners L P/il
director, other
AGrant or award
Pre-Funded Warrantderivative
+160,107$9.08$1.5M313,548Dec 4, 2024
Jun 4, 2024G. Walmsley Graham
director
SOpen-market sale
Common Stockindirect: See note
-700,000$14.85$10M700,761Nov 26, 2024
Jun 4, 2024G. Walmsley Graham
director
SOpen-market sale
Common Stockindirect: See note
-475,000$14.85$7.1M708,114Nov 26, 2024
Nov 15, 2024Shane William Charles Kovacs
Ch. Operating & Financial Off.
MOption exercise
Common Stock
+25,000$7.02$176k510,458Nov 18, 2024
Nov 15, 2024Shane William Charles Kovacs
Ch. Operating & Financial Off.
MOption exercise
Stock Option (Right to Buy)derivative
-25,000$0.00$0162,000Nov 18, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

OLMA insider trading: Olema Pharmaceuticals, Inc. | InsiderTell